Investor Relations

Overview

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. Our first commercial product, Jakafi® (ruxolitinib), is approved in the United States for patients with intermediate or high-risk myelofibrosis and for patients with polycythemia vera who have had an inadequate response to or are intolerant to hydroxyurea. We have a diverse and growing portfolio of product candidates, including both small and large molecules.

Events & Presentations

Upcoming

October 30, 2018 8:00 AM EDT
Q3 2018 Incyte Corporation Earnings Conference Call

Prior

September 13, 2018 10:00 AM EDT
Morgan Stanley 16th Annual Global Healthcare Conference

July 31, 2018 8:00 AM EDT
Q2 2018 Incyte Corporation Earnings Conference Call

June 21, 2018 1:00 PM EDT
2018 Investor & Analyst Event

SEC Filings

Filing date Description Filing Group View

424B7    

Registration Statements

424B7    

Registration Statements

424B7    

Registration Statements

Investor Contacts

Michael Booth D.Phil
Vice President, Investor Relations
Phone: 302.498.5914
E-mail: mbooth@incyte.com

Lauren Kwiecinski
Senior Director, Investor Relations
Phone: 302.498.6141
E-mail: lkwiecinski@incyte.com

Computershare
P.O. Box 43078
Providence, RI 02940-3078 Phone: 877.272.1536